FAQ: Nutriband Inc. CEO Transition and AVERSA Fentanyl Development Timeline

What is the main announcement in this press release?

Nutriband Inc. announced that company founder Gareth Sheridan has resumed his role as CEO effective immediately, replacing Co-Founder and Chairman Serguei Melnik who temporarily served in the position.

What is AVERSA Fentanyl and what does it do?

AVERSA Fentanyl is Nutriband’s flagship abuse-deterrent opioid patch designed to prevent misuse, abuse, diversion, and accidental exposure of fentanyl using the company’s proprietary AVERSA technology.

What is the development timeline for AVERSA Fentanyl?

Sheridan will lead the company through its final 2025 development framework toward an expected 2026 NDA (New Drug Application) filing with regulatory authorities.

What is the commercial potential for AVERSA Fentanyl?

Potential peak annual U.S. sales for AVERSA Fentanyl are estimated between $80 million and $200 million, representing significant market opportunity for the abuse-deterrent opioid patch.

How is the AVERSA technology protected?

The AVERSA technology is protected by patents in 46 countries, including major markets such as the United States, Europe, and Japan, providing strong intellectual property protection.

What is Nutriband Inc.’s primary business focus?

Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products, with AVERSA Fentanyl being their lead product under development using their proprietary abuse-deterrent technology.

Where can investors find more information about Nutriband?

Investors can visit the company’s website at www.nutriband.com or access the latest news and updates in the company’s newsroom at https://ibn.fm/NTRB for ongoing developments.

What makes the AVERSA technology significant?

The AVERSA technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, addressing a critical public health concern.